The Library
A novel, long-acting glucagon-like peptide receptor-agonist : dulaglutide
Tools
Tools
Tools
Gurung, Tara, Waugh, Norman, O'Hare, J. Paul and Shyangdan, Deepson S. (2015) A novel, long-acting glucagon-like peptide receptor-agonist : dulaglutide. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 8 . pp. 363-386. doi:10.2147/DMSO.S34418
Research output not available from this repository, contact author.
Official URL: http://dx.doi.org/10.2147/DMSO.S34418
Abstract
Background: Dulaglutide is a new, long-acting glucagon-like peptide analogue in the treatment of type 2 diabetes. It is available in two doses, 0.75 and 1.5 mg, given by injection once weekly. This systematic review reports the effectiveness and safety of dulaglutide in type 2 diabetes in dual and triple therapy.
Methods: MEDLINE, MEDLINE In-Process and Other Non-Indexed Citations, EMBASE, and conference abstracts were searched from 2005 to August 2014, and updated in January 2015. Company websites and references of included studies were checked for potentially relevant studies. European Medicines Agency and US Food and Drug Administration websites were searched.
Results: Four trials were included. All were manufacturer-funded randomized controlled trials from the Assessment of Weekly Administration of Dulaglutide in Diabetes (AWARD) program. AWARD-1 compared dulaglutide 1.5 mg against exenatide 10 µg twice daily and placebo, AWARD-2 compared dulaglutide 0.75 and 1.5 mg against insulin glargine, AWARD-5 compared dulaglutide 0.75 and 1.5 mg against sitagliptin 100 mg and placebo, and AWARD-6 compared dulaglutide 1.5 mg against liraglutide 1.8 mg. The duration of follow-up in the trials ranged from 26 to 104 weeks. The primary outcome of all the included trials was change in HbA1c. At 26 weeks, greater HbA1c reductions were seen with dulaglutide than with twice daily exenatide (dulaglutide 1.5/0.75 mg: −1.5%/−1.3%; exe: 0.99%) and sitagliptin (1.5/0.75 mg −1.22%/−1.01%; sitagliptin: −0.6%). HbA1c change was greater with dulaglutide 1.5 mg (−1.08%) than with glargine (−0.63%), but not with dulaglutide 0.75 mg (−0.76%). Dulaglutide 1.5 mg was found to be noninferior to liraglutide 1.8 mg. More patients treated with dulaglutide achieved HbA1c targets of <7% and ≤6.5%. Reduction in weight was greater with dulaglutide than with sitagliptin and exenatide. Hypoglycemia was infrequent. The main adverse events were nausea, diarrhea, and vomiting.
Conclusion: Dulaglutide is effective in the treatment of patients with type 2 diabetes but we need long follow-up data for safety concerns.
| Item Type: | Journal Article | ||||||
|---|---|---|---|---|---|---|---|
| Divisions: | Faculty of Medicine > Warwick Medical School > Health Sciences Faculty of Medicine > Warwick Medical School |
||||||
| Journal or Publication Title: | Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy | ||||||
| Publisher: | Dove Press | ||||||
| ISSN: | 1178-7007 | ||||||
| Official Date: | 10 August 2015 | ||||||
| Dates: |
|
||||||
| Volume: | 8 | ||||||
| Page Range: | pp. 363-386 | ||||||
| DOI: | 10.2147/DMSO.S34418 | ||||||
| Status: | Peer Reviewed | ||||||
| Publication Status: | Published | ||||||
| Access rights to Published version: | Open Access |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
